ATHENA-2 CAR T / EdiGene - LARVOL DELTA

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Trial completion date: Jul 2027 ➔ Feb 2028 | Initiation date: Jul 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2026 ➔ Feb 2027

CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology